Advisory Board

The Precision Medicine Institute Advisory Board helps to ensure that our content guides hospital and health system executives in the strategic challenges of their precision medicine programs

Pranil Chandra

Pranil K. Chandra, DO, FCAP, FASCP
Chief Medical Officer of Genomic
and Clinical Pathology
Brentwood, TN

Pranil K. Chandra, DO, FCAP, FASCP

Dr. Chandra joined PathGroup in 2011 as Associate Medical Director of Molecular Pathology and now currently serves as Chief Medical Officer of Genomic and Clinical Pathology Services at PathGroup. Dr. Chandra holds board certifications in anatomic and clinical pathology, hematopathology, and molecular genetic pathology. He completed his AP/CP training and fellowships in hematopathology, oncologic pathology, and molecular pathology at NYU Langone Medical Center and the University of Texas-MD Anderson Cancer Center, respectively. While at MD Anderson, Dr. Chandra served as Chief Fellow and received numerous awards for his research in acute myeloid leukemia. He has presented numerous abstracts and platform presentations at various pathology meetings and has published peer-reviewed articles and book chapters. Dr. Chandra is a member of the American Society of Clinical Pathology, Association of Molecular Pathology, where he also serves in a leadership capacity to the Economic Affairs and Clinical Practice Committees. Dr. Chandra is a medical consultant in molecular pathology and personalized medicine and is considered a national thought leader in precision medicine and cancer genomics.

Michael Clare-Salzler, MD

Dr. Clare-Salzler received his medical degree and internal medicine training from the State University of New York at Buffalo. He began his clinical endocrinology and immunology research career at the University of California in Los Angeles, where he studied the immunopathogenesis of type 1 diabetes. Dr. Clare-Salzler maintains an active practice in endocrinology, treating patients with diabetes and other endocrine diseases as well as an active research program. He has also played a leadership role in the development of the clinical molecular pathology laboratory and the Precision Medicine program at the University of Florida School of Medicine.

Michael Clare-Salzler MD

Michael Clare-Salzler, MD
Chair of Pathology
University of Florida School of Medicine
Gainesville, FL

James Crawford

James M. Crawford, MD, PhD
Professor and Chair, Pathology and Laboratory Medicine
Donald and Barbara Zucker School of Medicine at Hofstra/Northwell
Great Neck, Hempstead, NY

James M. Crawford, MD, PhD

Dr. Crawford oversees the integrated laboratory network for Northwell Health, which includes 23 hospital-based clinical laboratories; the health system’s integrated pathology practice; and the centralized Core Laboratory that serves Northwell and, through the CLNY Alliance, the 15 hospitals of Health + Hospitals of New York City.

Dr. Crawford is a leading proponent of the role of pathology and the clinical laboratory industry in patient-centered care and value-based care. He provides national leadership in developing the value statements for laboratory diagnostic services, which includes being a founding member of Project Santa Fe and the concept of “Clinical Laboratory 2.0.” The latter’s goal is for clinical laboratories to support a proactive, integrative paradigm of health care, taking particular advantage of the vast store of latent information in the data routinely generated through clinical laboratories. This is then coupled with opportunities in precision medicine, as through genomics, biobanking, and informatics.

Author of more than 260 publications, Dr. Crawford is editor-in-chief of Academic Pathology, the official journal of the Association of Pathology Chairs (APC). He received his MD and PhD from Duke University School of Medicine, and he completed post-graduate training in anatomic pathology and gastrointestinal pathology at Brigham and Women's Hospital, followed by a fellowship in hepatic pathology at the Royal Free Hospital in London.

Jordan Seth Laser, MD

Dr. Laser is a board-certified anatomic, clinical, and molecular genetic pathologist. Currently employed at Northwell Health System in New York, Dr. Jordan serves the Department of Pathology and Laboratory Medicine in the following roles: Medical Director, LIJ Pathology and Laboratory Medicine; Associate Medical Director, Core Laboratories; Senior Director, Division of Cytogenetics and Molecular Pathology; and Director, Division of Near Patient Testing. His expertise includes molecular and genomic medicine, laboratory management, healthcare finance, and standards and regulations.

Jordan Seth Laser

Jordan Seth Laser, MD
Associate Professor
Donald and Barbara Zucker School of Medicine at Hofstra/Northwell
Member, College of American Pathology Personalized Medicine Committee
New Hyde Park, NY


Elke Nelson-Nichols, PhD, MBA
Director of Research Strategy and Operations
Tempus Labs
Chicago, IL

Elke Nelson-Nichols, PhD, MBA

Dr. Nelson-Nichols serves as Director of Research Strategy and Operations at Tempus Labs. To inform research strategy and enable operational excellence, she works closely with pharma and biotech organizations to understand how Tempus' multimodal data and technology can best support their needs across drug discovery, clinical trial optimization, and asset positioning. Dr. Nelson-Nichols initially joined Tempus in March 2021, as a Director of Life Sciences Alliance Management, responsible for orchestrating internal teams and efforts to maximize the value of Tempus' offerings to its existing partners.
Prior to joining Tempus, she spent nearly a decade at ECRI institute, where she worked closely with executive leadership to identify, explore, and execute on opportunities that supported the organization's mission to advance effective, evidence-based healthcare globally. Dr. Nelson-Nichols had joined ECRI in July 2011 as a senior clinical writer for an online horizon-scanning database that predicts potential impacts of up-and-coming healthcare technologies. In June 2014, she transitioned from an internal role as a content team leader to an external role working directly with members of ECRI’s Health Technology Assessment (HTA) Service to support health systems and third-party payers in their use of ECRI’s evidence tools to inform decision making about healthcare technology adoption, implementation, and coverage. In 2017, Dr. Nelson-Nichols took on a more strategic role as Assistant Director of ECRI’s HTA and ECRIgene Services. She continued to work directly with members in the field while participating in product and new business development, marketing strategies, and undertaking speaking engagements.